Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
Home
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)
Next Post
Previous Post
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Read More
Bryan Ball
Biomarker Analysis From AMPECT Correlating Response to
nab
-Sirolimus in PEComa With
TSC1
and
TSC2
Inactivating Alterations
KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor
nab
-Sirolimus Show Improved Antitumor Activity
Phase I results from a phase 1/2 multi-center study of
nab
-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
nab
-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Correlation of
nab
-sirolimus tumor drug levels and improved tumor suppression in
KRAS G12C
non-small cell lung cancer xenografts treated with
nab
-sirolimus in combination with KRAS inhibitors
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.